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Coronary InterventionTo the Editor: Antiplatelet therapy is a cornerstone of treatment
for patients with acute myocardial infarction (MI)dparticularly
those treated with percutaneous coronary intervention (PCI)d
yet bleeding is a major side effect of its use and can lead to therapy
discontinuation (1). Premature antiplatelet therapy discontinuation
has been associated with increased risks of stent thrombosis, MI,
and death (2).
The TRANSLATE-ACS study (Treatment with ADP receptor
inhibitors-longitudinal assessment of treatment patterns and events
after acute coronary syndrome) is an observational study ofFigure 1 Post-Discharge Bleeding Among Patient Subgroups
Rate of post-discharge bleeding events among patient subgroups. AC ¼ anticoagulant; A
EQ-5D ¼ EuroQol 5-Dimension score; PHQ-2 ¼ patient health questionnaire-2 (depressioST-segment elevation and non–ST-segment elevation MI patients
treated with PCI in the United States (3). The TRANSLATE-
ACS study offers insight to the incidence of and response to early
post-discharge bleeding in a contemporary MI population treated
with clopidogrel or more potent adenosine diphosphate receptor
inhibitors (ADPri) in routine practice.
This analysis included 9,177 MI patients who were discharged
alive on ADPri therapy from 219 United States hospitals from
April 2010 to October 2012. At the 6-week follow-up interview,
patients were asked to report any bleeding/severe bruising since
discharge and any change in ADPri therapy. All bleeding-related
repeat hospital stays and major adverse cardiovascular events
(MACE)ddeﬁned as death, recurrent MI, stroke, or unplanned
coronary revascularizationdwere independently validated via
medical record review (3). Bleeding events were classiﬁed according
to the Bleeding Academic Research Consortium (BARC) criteria.
We performed multivariable logistic regression modeling to
determine the association of discharge second-generation ADPri
(prasugrel or ticagrelor) use with bleeding, adjusting for covariates
from the CRUSADE bleeding risk model. We examined the as-
sociation of bleeding with 6-week risk of MACE with logistic
regression models adjusting for the ACTION mortality risk score.
Among 9,177 MI patients discharged on a regimen of ADPri
therapy, 1,264 (14%) reported early bleeding/severe bruising, and 91
patients (7% of patients who reported bleeding) were rehospitalized
with bleeding. Fatal bleeding occurred in 1 patient. There was no
coronary artery bypass grafting–related bleedingwithin the ﬁrst 6weeks
post-discharge; 3% were BARC type 3, and 54% were BARC type 2.DP ¼ adenosine diphosphate; CrCl ¼ creatinine clearance;
n); 2nd gen ¼ second-generation.
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1701Higher rates of post-discharge bleeding were observed among
patients who were female or white and those with lower func-
tional status or baseline depression (Fig. 1). The occurrence of
major bleeding during the index hospital stay did not predict a
higher rate of post-discharge bleeding. Patients discharged on a
regimen of a second-generation ADPri were more likely to have
early post-discharge bleeding than patients without bleeding.
After multivariable adjustment, discharge on a second-generation
ADPri regimen remained signiﬁcantly associated with higher
bleeding risk (odds ratio: 1.63, 95% conﬁdence interval: 1.41 to
1.87).
At 6 weeks post-MI, ADPri therapy was stopped or interrupted
in 7% of bleeding patients. Patients who reported bleeding were
more likely to permanently discontinue their ADPri than patients
without bleeding (4.5% vs. 2.7%, p ¼ 0.004), although overall
discontinuation rates were low. Notably, 28% of the patients who
discontinued their ADPri had recently received a drug-eluting
stent (DES). Early discontinuation was more common among
bleeding patients on a regimen of ﬁrst-generation than second-
generation ADPris (5.8% vs. 2.4%, p ¼ 0.009). Patients with
bleeding were also more likely to temporarily stop the ADPri than
patients without bleeding (2.6% vs. 1.6%, p ¼ 0.007), although
rates of temporary antiplatelet interruption were low. Rates of post-
discharge switch from a second-generation ADPri to clopidogrel
were not signiﬁcantly different between patients with and without
bleeding (6.6% vs. 5.7%, p ¼ 0.44).
Notably, 43% of post-discharge bleeding events were never
brought to clinical attention (BARC type 1), and 28% of ADPri
therapy changes in response to bleeding were made without cardio-
logist involvement. Patients who did not report bleeding to a clinician
were less likely to have had a follow-up outpatient appointment
made for them before discharge than patients who did bring bleeding
to clinical attention (66.3% vs. 70.2%, p ¼ 0.02).
Rates of MACE were 4.2%, 3.8%, 4.5%, and 13.2% among
patients with no bleeding, BARC type 1 bleeding, BARC type 2
bleeding, and BARC type 3 or higher bleeding, respectively. The
BARC type 3 or higher bleeding was associated with a higher
adjusted risk of MACE (odds ratio: 3.28, 95% conﬁdence interval:
1.27 to 8.47) compared with no bleeding.
The introduction of second-generation ADPri has raised the
concern that their greater potency would increase bleeding risk. In
our study, 1 in 7 post-MI patients on a regimen of contemporary
ADPri therapy experienced bleeding/severe bruising early after
discharge, yet repeat hospital stay for bleeding was rare. Only
BARC type 3þ bleeding was signiﬁcantly associated with higher
risk of MACE. Treatment with a second-generation ADPri was a
signiﬁcant factor associated with early bleeding; however, rates of
BARC type 3þ bleeding were low (<0.2%) among patients on a
second-generation ADPri regimen.
We observed low rates of early ADPri discontinuation in the
ﬁrst 6 weeks post-discharge, yet more than one-quarter of ADPri
discontinuations occurred in the setting of recent DES implanta-
tion. Only one-half of bleeding events were brought to clinical
attention, and a substantial proportion of patient decisions to pre-
maturely discontinue ADPri therapy were made without cardiologist
input. Patients commonly cite poor communication and lack of
knowledge about the duration and purpose of treatment as the
primary reasons for antiplatelet therapy discontinuation (4). In our
study, patients who did not have a follow-up outpatient appointment
arranged before discharge were less likely to report their bleedingevent to a clinician. Therefore, ensuring early clinical follow-
updparticularly for patients at higher risk of bleeding (e.g., women,
lower baseline functional status, discharge on a second-generation
ADPri regimen, or concurrent oral anticoagulant prescription)d
might be a key ﬁrst step in both raising subsequent bleeding events
to clinical attention and avoiding premature ADPri discontinua-
tion. Although the risk of bleeding was higher among patients
discharged on a regimen of second-generation ADPris, the rate of
early treatment discontinuation did not differ signiﬁcantly between
ﬁrst- and second-generation agents.
In conclusion, bleeding occurs commonly in the early period after
discharge among MI patients treated with PCI and ADPris and is
not always brought to clinical attention. Although premature
ADPri discontinuation was infrequent, a substantial proportion of
these discontinuations occurred in the setting of recent DES
implantation and without cardiologist input, indicating the need
for continued patient education and close post-acute MI moni-
toring. Bleeding risk was higher among patients prescribed second-
generation ADPris; however, use of these agents was not associated
with higher rates of early antiplatelet therapy cessation.*Tracy Y. Wang, MD, MHS, MScy
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